Literature DB >> 29348317

Head-to-Head Comparison of 11C-PBR28 and 18F-GE180 for Quantification of the Translocator Protein in the Human Brain.

Paolo Zanotti-Fregonara1, Belen Pascual2, Gaia Rizzo3,4, Meixiang Yu2, Neha Pal2, David Beers2, Randall Carter5, Stanley H Appel2, Nazem Atassi6, Joseph C Masdeu2.   

Abstract

18F-GE180 is a third-generation PET tracer for quantifying the translocator protein (TSPO), a biomarker for inflammation. The aim of this study was to perform a head-to-head comparison of 18F-GE180 and the well-established TSPO tracer 11C-PBR28 by scanning with both tracers during the same day in the same subjects.
Methods: Five subjects underwent a 90-min PET scan with 11C-PBR28 in the morning and 18F-GE180 in the afternoon. A metabolite-corrected arterial input function was obtained in each subject for both tracers, and the brain uptake was quantified with a 2-tissue-compartment model.
Results: The rate of metabolism of 18F-GE180 in arterial blood was slower than that of 11C-PBR28 (the percentages of nonmetabolized parent in plasma at 90 min were 74.9% ± 4.15% [mean ± SD] and 11.2% ± 1.90%, respectively). The plasma free fractions were similar for both tracers: 3.5% ± 1.1% for 18F-GE180 and 4.1% ± 1.1% for 11C-PBR28. The average total volume of distribution (VT) of 18F-GE180 was about 20 times smaller than that of 11C-PBR28 (0.15 ± 0.03 mL/cm3 for 18F-GE180 and 3.27 ± 0.66 mL/cm3 for 11C-PBR28). 18F-GE180 was characterized by poor transfer from the vascular compartment to the brain (its plasma-to-tissue rate constant [K1] was about 10 times smaller than that of 11C-PBR28). Moreover, kinetic modeling was more difficult with 18F-GE180, as its VT values were identified with a lower precision than those of 11C-PBR28 and outlying values were more frequent.
Conclusion: The VT of 18F-GE180 was about 20 times smaller than that of 11C-PBR28 because of low penetration into the brain from the vascular compartment. In addition, kinetic modeling of 18F-GE180 was more challenging than that of 11C-PBR28. Therefore, compared with 11C-PBR28, 18F-GE180 had unfavorable characteristics for TSPO imaging of the brain.
© 2018 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  11C-PBR28; 18F-GE180; TSPO

Mesh:

Substances:

Year:  2018        PMID: 29348317     DOI: 10.2967/jnumed.117.203109

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  24 in total

1.  The validity of 18F-GE180 as a TSPO imaging agent.

Authors:  Paolo Zanotti-Fregonara; Mattia Veronese; Belen Pascual; Robert C Rostomily; Federico Turkheimer; Joseph C Masdeu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-17       Impact factor: 9.236

2.  Letter to the Editor re: Confirmation of Specific Binding of the 18-kDa Translocator Protein (TSPO) Radioligand [18F]GE-180: a Blocking Study Using XBD173 in Multiple Sclerosis Normal Appearing White and Grey Matter.

Authors:  Paolo Zanotti-Fregonara; Mattia Veronese; Gaia Rizzo; Belen Pascual; Joseph C Masdeu; Federico E Turkheimer
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

3.  Confirmation of Specific Binding of the 18-kDa Translocator Protein (TSPO) Radioligand [18F]GE-180: a Blocking Study Using XBD173 in Multiple Sclerosis Normal Appearing White and Grey Matter.

Authors:  Sujata Sridharan; Joel Raffel; Ashwini Nandoskar; Chris Record; David J Brooks; David Owen; David Sharp; Paolo A Muraro; Roger Gunn; Richard Nicholas
Journal:  Mol Imaging Biol       Date:  2019-10       Impact factor: 3.488

4.  Comparison of Invasive and Non-invasive Estimation of [11C]PBR28 Binding in Non-human Primates.

Authors:  Lucero Aceves-Serrano; Vesna Sossi; Doris J Doudet
Journal:  Mol Imaging Biol       Date:  2021-10-07       Impact factor: 3.488

Review 5.  Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica.

Authors:  Kornelis S M van der Geest; Maria Sandovici; Pieter H Nienhuis; Riemer H J A Slart; Peter Heeringa; Elisabeth Brouwer; William F Jiemy
Journal:  Front Med (Lausanne)       Date:  2022-06-06

6.  18F-GE180, a failed tracer for translocator protein, has no place in child abuse imaging.

Authors:  Paolo Zanotti-Fregonara; Gaia Rizzo; Mattia Veronese; Robert B Innis; Federico E Turkheimer
Journal:  Pediatr Radiol       Date:  2021-11-27

Review 7.  PET imaging of neuroinflammation in neurological disorders.

Authors:  William C Kreisl; Min-Jeong Kim; Jennifer M Coughlin; Ioline D Henter; David R Owen; Robert B Innis
Journal:  Lancet Neurol       Date:  2020-11       Impact factor: 44.182

8.  Impact of TSPO Receptor Polymorphism on [18F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders.

Authors:  Franziska J Vettermann; Stefanie Harris; Julia Schmitt; Marcus Unterrainer; Simon Lindner; Boris-Stephan Rauchmann; Carla Palleis; Endy Weidinger; Leonie Beyer; Florian Eckenweber; Sebastian Schuster; Gloria Biechele; Christian Ferschmann; Vladimir M Milenkovic; Christian H Wetzel; Rainer Rupprecht; Daniel Janowitz; Katharina Buerger; Robert Perneczky; Günter U Höglinger; Johannes Levin; Christian Haass; Joerg C Tonn; Maximilian Niyazi; Peter Bartenstein; Nathalie L Albert; Matthias Brendel
Journal:  Life (Basel)       Date:  2021-05-26

9.  [11C]PBR28 radiotracer kinetics are not driven by alterations in cerebral blood flow.

Authors:  Christin Y Sander; Stefano Bovo; Angel Torrado-Carvajal; Daniel Albrecht; Hongping Deng; Vitaly Napadow; Julie C Price; Jacob M Hooker; Marco L Loggia
Journal:  J Cereb Blood Flow Metab       Date:  2021-06-23       Impact factor: 6.960

Review 10.  Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact.

Authors:  Fabiola De Marchi; Ivana Munitic; Amedeo Amedei; James D Berry; Eva L Feldman; Eleonora Aronica; Giovanni Nardo; Donatienne Van Weehaeghe; Elena Niccolai; Nikolina Prtenjaca; Stacey A Sakowski; Caterina Bendotti; Letizia Mazzini
Journal:  Neurosci Biobehav Rev       Date:  2021-06-19       Impact factor: 9.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.